/* RM 168662 - Track viewing of recorded presentations */

The Autism Biomarkers Consortium for Clinical Trials: Study Design and Progress to Interim Analysis

J. C. McPartland1, S. J. Webb2, F. Shic3, A. Naples1, C. Sugar4, M. Murias5, J. Dziura6, C. Brandt7, R. A. Bernier8, K. Chawarska9, G. Dawson10, S. Faja11, S. Jeste12 and C. A. Nelson13, (1)Yale Child Study Center, Yale University School of Medicine, New Haven, CT, (2)Center, Seattle Children’s Research Institute & University of Washington, Seattle, WA, (3)Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, (4)Department of Biostatistics, UCLA, Los Angeles, CA, (5)Duke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (6)Emergency Medicine, Yale School of Medicine, New Haven, CT, (7)Yale University, New Haven, CT, (8)Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, (9)Child Study Center, Yale University School of Medicine, New Haven, CT, (10)Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, (11)Division of Developmental Medicine, Boston Children's Hospital / Harvard Medical School, Brookline, MA, (12)Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, (13)Department of Developmental Medicine, Boston Children's Hospital, Boston, MA